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The aim of this study was to investigate patient experiences of living with 4 
monoclonal gammopathy of undermined significance (MGUS). Living with a 5 
premalignant condition such as MGUS may elicit negative psychosocial effects 6 
including increased anxiety and fear of progression to cancer. To date, no study 7 
utilising qualitative methodology has explored the lived experiences of MGUS 8 
patients. 9 
Methods: 10 
Data was collected via two focus groups and six telephone interviews. MGUS patients 11 
(n=14) were recruited via nurse-led hematology telephone-clinics in Northern 12 




Thematic analysis identified 3 overarching themes; (1) The psychosocial impact of an 17 
MGUS diagnosis, (2) Knowledge of MGUS and (3) Experiences of MGUS health 18 
services. Patients with MGUS reported experiencing poor psychological adjustment 19 
to their condition particularly at the point of diagnosis and approaching follow-up 20 
appointments. Feelings of isolation, poor information-provision, increased 21 
uncertainty and limited psychosocial support for MGUS patients were also reported. 22 
Patients did however reflect positively on their experience of being followed up via 23 
nurse-led telephone clinics.   24 
 25 
Conclusions: 26 
Provision of patient friendly information guides at diagnosis, and additional 27 
psychosocial support services such as nurse-led telephone clinics and coordinated 28 
patient groups may help MGUS patients adjust better to their diagnosis and in doing 29 
so improve quality of life in this patient population. 30 
 31 
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Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic 6 
premalignant blood disorder which precedes multiple myeloma (MM), an incurable 7 
B-cell malignancy (Kyle et al., 2006). The annual rate of progression to MM and 8 
related lymphoproliferative disorders such as Waldenström’s macroglobulinemia, and 9 
lymphoma has been reported to be 1% (Kyle et al., 2002), meaning the vast majority 10 
of individuals diagnosed with MGUS will not progress to MM. MGUS is more 11 
common in males (Wadhera and Rajkumar, 2010), and individuals of black ethnicity 12 
(Landgren et al., 2007, 2006). Younger age at diagnosis has been reported among 13 
black individuals (median age of diagnosis: 66 vs 70 years old (white individuals ) 14 
(Landgren et al., 2017). MGUS prevalence is estimated to be 3.2% in adults over 50 15 
years old, however, most individuals remain undiagnosed due to the asymptomatic 16 
nature of presentation (Kyle et al., 2006; Therneau et al., 2012).  17 
 18 
MGUS patients often experience considerable hospital activity pre- and post- 19 
diagnosis, implying diagnosed cases are living with comorbidities (Lamb et al., 2019). 20 
MGUS is typically detected incidentally during investigations for other conditions, 21 
with an elevated total protein level leads to serum protein electrophoresis (SPE) 22 
which detects a paraprotein (International Myeloma Working Group, 2003; Kyle et al., 23 
2010). Individuals are diagnosed when a reduction of one or more immunoglobulin 24 
class (IgG, IgA and IgM) levels are detected from a serum protein electrophoresis 25 
(SERP) test (Bird et al., 2009). The International Myeloma Working Group (IMWG) 26 
defines the parameters of MGUS as having a serum M protein <30g/l, <10% clonal 27 
plasma cells (PCs) in the bone marrow and, most importantly, the absence of end-28 
organ damage that can be attributed to the PC proliferative disorder or other B-cell 29 
proliferative disorders (International Myeloma Working Group, 2003; Kyle et al., 30 
2010).  Once diagnosed, it is recommended that MGUS patients are followed-up 31 
regularly (every 3-12 months) to identify early signs of progression to MM (Bird et al., 32 





specialists (CNS) utilising telephone clinics for low-risk patients; under the guidance 1 
of haematology consultants (Rawstron et al., 2007). 2 
 3 
Studies investigating the quality of life of patients with haematological precancerous 4 
conditions is limited. Recent quantitative cross-sectional research on MGUS and 5 
smouldering multiple myeloma (another higher risk MM precursor) has indicated 6 
that these patients exhibit similar psychological distress and mental health-related 7 
quality of life (HRQoL) as patients with active MM (cancer) (Maatouk et al., 2019). 8 
Compared to MM, MGUS is considered to be asymptomatic with the literature 9 
suggesting minimal physical impact (Kyle et al., 2011). Similar qualitative studies of 10 
other precancerous conditions, such as Barrett’s oesophagus, identified a lack of 11 
social support, poor information provision and negative psychological reactions, e.g. 12 
increased anxiety, as central concepts of living with a diagnosis of a premalignant 13 
condition (Kennedy et al., 2012; Lee Mortensen and Adeler, 2010). This study aimed 14 
to illustrate the experiences of receiving and living with a MGUS diagnosis. 15 
 16 
Methods  17 
Design 18 
This study was a qualitative design, which utilised an integration of focus groups and 19 
telephone interviews to collect and integrate the data. The Consolidated Criteria for 20 
Reporting Qualitative Studies (COREQ) (Tong, Sainsbury, & Craig, 2007) guided the 21 
reporting of the study.  Participants were identified using convenience sampling and 22 
recruited during their routine telephone surveillance appointment by CNS’ at two 23 
Healthcare trusts (Belfast and Southern) in Northern Ireland. During these 24 
appointments the CNS discusses patient’s blood test results and assesses their 25 
general health; with a goal of identifying potential signs of progression such as 26 
increased infections, bone pain and/or fractures (Rawstron et al., 2007). All patients 27 
on telephone follow-up were considered low risk for progression.   28 
 29 
Prior to invitation, the CNS assessed each patient against eligibility criteria. 30 
Individuals were not eligible if they were considered to be too frail or had 31 
neurocognitive difficulties or severe mental health issues which could affect their 32 
ability to provide consent. The CNS introduced the study to participants during their 33 
routine telephone appointment. Interested patients were mailed a study information 34 





sheet, a pen and a prepaid envelope to return the consent and contact information 1 
forms) by the CNS. Suitable times for the focus group/interview were then organised 2 
by the university-based study team by telephone call. Non-responders received a 3 
reminder telephone call from the CNS after two weeks. No patient had a prior 4 
relationship with the research team; the latter was separate to the clinical team 5 
involved in recruitment.  Prior to recruitment, study documentation was reviewed by 6 
a subset of (non-MGUS) patients in the Northern Ireland Clinical Trials Centre 7 
‘Personal and Public Involvement in Research’ committee. 8 
 9 
Both the interviews/focus groups followed a semi-structured schedule (Appendix 1) 10 
developed by the study team in consultation with the published literature. Data was 11 
collected via two focus groups and six telephone interviews with MGUS patients 12 
aged 40-70 years old in 2015-16. Poor focus group recruitment led to incorporating 13 
telephone interviews to increase numbers and provide a wider range of opinions and 14 
individuals (Stokes and Bergin, 2006). Patients were offered the choice with all 15 
preferring the interviews. This multi-method monostrand design (combining focus 16 
groups and interviews) a more holistic approach to the data richness (Barbour, 2014). 17 
A critical review endorsed this integration of the methods as it “leads to an enhanced 18 
description of the phenomenon’s structure and its essential characteristics” (Stokes 19 
and Bergin, 2006).  20 
 21 
Focus groups were led by an experienced qualitative researcher (OS or CT; both 22 
female with expertise outside MGUS field) while two other study team members 23 
(CMcS and BB; both female with expertise in the area) attended to take notes and 24 
assist with logistics. Focus groups took place within a non-clinical setting and lasted 25 
approximately one and a half hours. Telephone interviews lasted approximately 30 26 
minutes and were conducted by BM (male with MGUS research expertise). Focus 27 
groups and interviews were recorded on a digital voice recorder, transcribed 28 
verbatim, and rechecked against the recordings and relevant field notes. Recruitment 29 
was carried out until a point of saturation meaning that “sufficient data to account 30 
for all aspects of the phenomenon were obtained” (Morse et al., 2002). Draft 31 
transcripts (one-page extract) were sent to a subset of patients (n=7) for respondent 32 
validation. 33 
 34 
Data analysis  35 
Transcripts were analysed using inductive thematic analysis (Braun and Clarke, 2006) 36 





were conducted and data were gathered, coded and analysed by at least two 1 
researchers independently and then these data rounds were discussed by the two 2 
researchers and presented to members of the wider interdisciplinary research team 3 
for further analytical discussion. The iterative rounds continued until there was 4 
agreement that no new data or no new themes emerged from the transcripts. The 5 
data was organised using NVIVO v11 (QSR International Pty Ltd, 2015). Theme 6 
development was similar between the data collection methods. Verbatim quotations 7 
were used to provide evidence for the researchers’ interpretations. 8 
 9 
 10 
Ethics considerations 11 
Ethical approval was obtained from the Office for Research Ethics Committee 12 
Northern Ireland (Ref: 13/NI/0073). Informed consent was obtained from all study 13 
participants. A distress protocol was in place due to the potential for participants to 14 
become distressed while recalling their lived experiences. At the end of the focus 15 
group/telephone interview, participants were provided with an information pack via 16 
post; containing an information leaflet and contact details for charitable agencies 17 
(example, Myeloma UK\Bloodwise) for additional information or support if interested.  18 






In total, 14 individuals participated in this study: n=8 focus group participants (focus 2 
group 1 n=6, focus group 2, n=2), and six participated in telephone interviews (TI 1-3 
6). The participants were predominantly male (n=8/14), married (n=13/14) and 4 
educated to at least GCSE or O-level/high school standard (n=14) (Table 1). All 5 
patients were being followed-up for their MGUS diagnosis via nurse-led telephone 6 
clinic at 3-12 month intervals. Patients varied on time since diagnosis (from <1 year 7 
to >8 years). Six patients reported co-morbid long-term conditions (specific 8 
information on these conditions were not captured).  9 
Thematic analysis identified 3 overarching themes; (1), The psychosocial impact of an 10 
MGUS diagnosis, (2) Knowledge of MGUS and (3) Experiences of MGUS health 11 
services, Figure 1.  12 
 13 
Table 1 Demographic characteristics of the patients 14 
 15 
Table 2 Sociodemographic factors of individual patients  16 
Figure 1. Coding tree for themes and subthemes. 17 





The psychosocial impact of an MGUS diagnosis  1 
The first major theme identified was the psychosocial challenges of an MGUS 2 
diagnosis and how this fluctuated across the MGUS pathway. In particular, patients 3 
discussed heightened emotions at diagnosis, including shock and fear. Interaction 4 
with cancer services also invoked social comparisons with cancer patients and 5 
increased fears of progression.  6 
 7 
Patients described their diagnosis as “the shock of my life” (TI.2), with some viewing 8 
their diagnosis as an existential threat to their future. Patients reported completing 9 
wills and purchasing cemetery plots. These patients wanted more information and 10 
appeared to have been more anxious at diagnosis than other participants. However, 11 
all patients were aware of the potential for progression to cancer and reported some 12 
initial anxiety relating to this.  13 
“To realise that this had the potential to be cancerous was a shock and it certainly 14 
made me think about my mortality which I had-…obviously had thought about 15 
before but I thought about it even more and I did make a will and I did buy a grave 16 
(laughing). Basically I thought “Right I better start getting organized, just in case this 17 
leads to something awfully terrible”. TI.2 18 
For many patients, the shock developed into anxiety post-diagnosis; with patients 19 
describing consistent thoughts about their mortality during this time. The impact of 20 
the diagnosis and hearing the term ‘cancer’ led to some missing important MGUS 21 
information during the initial consultation. This shock and anxiety was present until 22 
their follow-up appointment, usually 3 months’ post-diagnosis; when patients could 23 
ask questions and process the information better.  24 
 25 
The psychosocial impact seemed to reduce over time; as patients came to terms with 26 
their condition. Most patients had lived with MGUS for many years and their worries 27 
about the consequences lessened over time. Their fear of progression to cancer was 28 
compared to “Damocles sword” FG2.2; a consistent but mainly dormant fear. Their 29 
fear that their next appointment could be the appointment they received bad news 30 
from the CNS and had progressed to cancer.  31 
“I think it's sort of a Damocles, hanging very high-- you know, it sort of-- not likely-- 32 






For some patients, MGUS was a spur to improve their lives and make lifestyle 1 
changes, with patients reporting increased physical activity and improving their diet 2 
to lessen their risk of progression.  3 
“I'm trying to do a bit of running. So it maybe gave me a little bit a kick in the 4 
backside to go out and do something, lose a bit weight. It's-- it was good that way. 5 
Was it because of that? Yeah, but that was only maybe more in the mind to, you 6 
know, I've got to do something to look after. I thought I was going to die from a 7 
heart [condition] rather than of MGUS”. FG2.2 8 
 9 
MGUS was often overshadowed by medical issues of friends/family, especially if 10 
cancer-related. Patients felt that their MGUS diagnosis was less important and tried 11 
to avoid causing worry and anxiety by not talking about their MGUS diagnosis. As a 12 
result, some patients felt isolated with their diagnosis; having no-one to speak to 13 
about their worries. Male participants were particularly reluctant to speak about their 14 
MGUS diagnosis due to their lack of understanding about the condition and burden 15 
this may place on their families/friends. The asymptomatic nature led to some 16 
patients comparing it to a mental health diagnosis; where patients were healthy on 17 
the outside but unwell inside. 18 
“Cause it's asymptomatic, so there are no symptoms associated with MGUS. It's 19 
seems to be that it's a hidden illness. So that may be one of the reasons why people 20 
don't really know much about it.”  FG2.2 21 
 22 
Patient’s knowledge of MGUS 23 
The second major theme identified was how patient’s knowledge of MGUS affected 24 
the MGUS experience; particularly around acquiring knowledge from HCPs and the 25 
Internet. While some patient-friendly information helped patients to be more 26 
confident about their diagnosis and take an active role in their own care, poor 27 
information led to decreased psychosocial wellbeing.   28 
 29 
Patients found the full name (monoclonal gammopathy of undetermined 30 
significance) difficult to understand, remember and explain to others; such as family 31 
and friends. Confusion was heightened by the differing terminology used by HCPs 32 
when they were trying to explain the condition to patients. Patients reported that 33 





protein” (TI.4)”, “benign blood abnormality” (TI.2) and a “rogue blood in my system”  1 
(TI.3). Many felt this was a contributing factor to their confusion and anxiety at 2 
diagnosis.  3 
“What does the word (MGUS)-- what does the 4 letters mean?” FG1.2 4 
“Monoclonal gammopathy of undermined significance.”  Interviewer: 5 
“And that's why nobody can remember it.”  FG1.2 6 
 7 
There were significant differences in patient’s actual and desired level of knowledge. 8 
Some patients reported wanting to “live in a bubble” (FG1.3) and did not wish to 9 
know anything beyond the essential information; such as when their appointments 10 
were. On the other hand, other patients kept detailed records of their blood scores 11 
(e.g. free-kappa-lambda ratio). For these patients, feeling informed created a sense 12 
of empowerment through feeling that they were an active participant of their care. 13 
These patients were able to describe the link between MGUS and MM and 14 
lymphoma and define the progression risk to MM “1% per annum“ (TI.4). Other 15 
patients reported their knowledge as low to medium and many desired to improve 16 
their knowledge. 17 
 18 
Patients who did not receive information leaflets at diagnosis reported more 19 
extensive online knowledge seeking than those who did. Patients described their 20 
experiences of searching for MGUS information online as challenging and websites 21 
difficult to navigate; with most of the information using unfamiliar and complex 22 
language or referring to information in other countries (especially the USA). As a 23 
result, many patients were linked/directed to MM (not MGUS) information, which 24 
caused significant anxiety and worry particularly if identified shortly after diagnosis. 25 
Patients illustrated how they found negative and fear-inducing stories when 26 
searching online at diagnosis; as they lacked the understanding to differentiate 27 
MGUS and MM information.  28 
“I sort of looked up what MGUS was .I looked up online and I sort of had a fair idea 29 
what it was well sort of an idea what it was so I was probably a wee bit apprehensive 30 
because I thought it’s possible-…I could not have cancer but I could possibly be 31 






Patients interacted with HCPs in order to gain information in relation to MGUS to 1 
educate and empower themselves. Patients sought information from three types of 2 
HCP; their haematology team (doctors and clinical nurse specialists), their GP and 3 
personal contacts within healthcare who were HCPs. 4 
 5 
Patients described how receiving good communication from their haematology team 6 
at diagnosis facilitated less anxiety and greater understanding. Good communication 7 
was described as the HCP taking the time to explain the condition and providing 8 
written materials at diagnosis. 9 
“No information sheet, nothing. You were just kind of sent away. And I actually had 10 
to try and remember what it was, because as everybody knows, when you're in with a 11 
medical professional you probably retain about a quarter of what they said. So I 12 
came way, and the only thing I remembered was Mono. And I thought, "What was 13 
that? What was the rest of that?" And I was trying to remember, cause that was it.”  14 
FG1.5 15 
 16 
Patients described how GPs were important providers of information, where they had 17 
their blood tests and general healthcare but generally reported poor MGUS-specific 18 
knowledge. Patients reported they often felt more knowledgeable than their GP 19 
about MGUS. Patients who reported that their GPs were knowledgeable about MGUS 20 
appeared to better understand their diagnosis and felt reassured that they were 21 
receiving the best care possible. Patients were aware that GPs (and HCPs in general) 22 
have limited time available to inform themselves about all conditions, especially 23 
uncommon conditions like MGUS; but felt less anxious when their GP was 24 
knowledgeable. Patients wanted more GP-related resources to help GPs and patients, 25 
however, there was little indication as to what form these resources could take. 26 
“So after the information, what I was told, it sinks in. and you do hear things like "you 27 
should be ok" [Laugh] Um, but when it sinks in, your first port of call, beyond the 28 
internet, is the GP. So I placed a call to the GP, and said to me "I don't know. I’ve 29 
never heard of this". FG1.5 30 
“My doctor (GP) was on top of it the whole time like my doctor’s been really good, 31 
and she has, she was she keeps me informed of everything that’s happening and she 32 
explains everything she’s my doctor. She’s one of the only doctors that speaks my 33 
language if you know what I mean. I have all the confidence of the day in her cause 34 






Patients whose relatives/friends were qualified health care professionals (such as 2 
doctors, nurses and pharmacists) reported improved knowledge and understanding 3 
of their condition post-diagnosis. Patients whose partners were healthcare staff 4 
described how they prepared questions for their appointments.  5 
“My wife (a nurse) had lists of questions, that she wanted me to ask. Now, and every 6 
time (Nurse Specialist) phones me now, I have those lists of questions now. FG1.6 7 
 8 
Experiences of MGUS related health services 9 
The final theme describes how patients were referred to MGUS health services and 10 
their experiences of health services and staff since diagnosis. Participants recalled 11 
different challenges and experiences, depending on the part of the patient pathway 12 
(pre-diagnosis, immediately post- diagnosis or a long-term MGUS patient) being 13 
discussed. 14 
 15 
Most patients described being diagnosed incidentally when being investigated for 16 
non-related medical issues, such as high blood pressure, co-morbidity appointments 17 
(e.g. asthma), hospitalisation for acute illness (e.g. pneumonia) and acute injuries (e.g. 18 
knee trauma). Typically, elevated paraprotein was initially investigated in the 19 
haematology department, which interviewees said was located within the “cancer 20 
centre”, which generated fear and anxiety for some patients.  21 
In one case, a patient previously under investigation for MM was relieved to have 22 
been diagnosed with MGUS; as they were not a “cancer patient” (FG1.1). Therefore, 23 
their experience of entering the MGUS health services was more positive than many 24 
of the other participants. 25 
“I have to say this, because this (location of haematology) really irked 26 
me, and I think it was because it was done over in (Local Hospital’s 27 
Cancer Centre). That very place. God bless everyone”. FG1.3 28 
 29 
All patients were under surveillance via a telephone clinic and are informed of the 30 
results of their surveillance-mandated blood tests by the haematology clinical nurse 31 
specialists. This typically includes a discussion of the blood result scores, inquiries 32 
about the patient’s general health and an opportunity for patient questions. Some 33 





overwhelmingly satisfied with telephone surveillance, with none discussing negative 1 
experiences. 2 
The telephone clinic offered an alternative to hospital-based consultant-led 3 
appointments by offering collaborative management between the haematology clinic 4 
and their primary care physician. The telephone clinic was reported to be more 5 
convenient and was especially beneficial for rural patients, for whom visiting the 6 
hospital and consultant in another town/city was seen as burdensome and time-7 
consuming. Patients also reported that telephone follow-up helped to reduce anxiety 8 
as they were able to avoid seeing cancer patients at the cancer centre (a reminder of 9 
what their diagnosis could progress to). Patients perceived the telephone clinic 10 
reduced burden on secondary care services (haematology staff especially 11 
doctors/consultants) and were supportive of improvements made to the service. 12 
“I think that -- that telephone follow up is --is a Godsend.“  FG1.6 13 
“The telephone clinic I think to me that’s probably really all I need it would seem, it 14 
would seem to me you know an awful waste of time to come down and taking up 15 
the doctor’s time in the hospital or anything I mean this is only a… quick telephone 16 
conversation”.  TI.4 17 
“Well, whenever I have the telephone appointment with the nurse I feel there’s a little 18 
bit-… I’m wondering what I’m going to be told am I getting worse or is my health 19 
deteriorating. So I’d be glad whenever the conversation’s finished.” FG2.1 20 
 21 
Despite an overall sense of satisfaction, most patients worried about the telephone 22 
clinic but realised that it was necessary. The waiting period between testing and 23 
results, which can be weeks, was highlighted as challenging. Patients reported 24 
anxiety during this waiting period and wondered if the blood tests would reveal an 25 
increase in disease markers and/or reveal progression to cancer (MM). 26 
 27 
Patients encountered a range of communication styles from healthcare professionals 28 
when being diagnosed and when they sought MGUS information. The style of 29 
communication mediated their experience of the health service and overall 30 
satisfaction. Some patients reported excellent psychosocial care, with clinicians 31 
(specialists and primary care physicians) taking time to explain the MGUS diagnosis, 32 
which led to less diagnosis-related anxiety with patients reporting that they felt 33 





communication style. Nurses provided reassurance, reduced anxiety and provided 1 
“peace of mind” through their psychosocial care, provision and explanation of 2 
information. Participants reported feeling more comfortable speaking with nurse 3 
specialists than doctors.  4 
 5 
Other patients reported fewer positive interactions with doctors and recalled how 6 
these negative experiences were linked to feelings of isolation and uncertainty about 7 
their diagnosis, especially immediately post-diagnosis. Some patient’s reported 8 
doctors in haematology not taking the time to describe their condition and being 9 
detached and dismissive of MGUS patients. While patients understood that other 10 
patients (especially cancer patients) required more care, they were disappointed at 11 
the lack of psychosocial care and empathy; with no/limited signposting to other 12 
information or being able to talk to someone about their diagnosis. This resulted in 13 
some patients having increased anxiety and feeling less informed. 14 
“Classic consultant. They go in and out of that every day, and they don't see it. They 15 
see people a lot worse that you. And they’re just delivering a line, to say, "Away you 16 
go". And the next patient in after you has got six months to live, or year. So they're 17 
focusing on him or her, rightly so.”. FG1.5 18 
 19 
Patients discussed a sense of isolation/uncertainty regarding their diagnosis, which 20 
many patients felt could be alleviated by providing support structures for meeting 21 
and interacting with other MGUS patients. MGUS patients are often not supported by 22 
cancer support charities or groups and can feel in “limbo” (FG1.1), both in cancer 23 
services and supportive structures such as the voluntary sector. Patients proposed 24 
developing two structures; in-person support groups (similar to cancer support 25 
groups) and volunteer peer support (local) contactable MGUS patients’ post-26 
diagnosis, for questions or concerns. Travel and low patient numbers were identified 27 
as threats to the long-term stability of in-person meet-ups. Focus group attendees 28 
(compared to telephone interviewees) were more positive about meetings/support 29 
groups. Some patients valued the availability of a contactable MGUS patient who 30 
they could speak to over a “coffee or glass of wine”  FG2.1. Developing this indirect 31 






“There's nothing (to help coping if individuals are struggling). you 1 
know, I just get through it, eventually. But it's not like I can lift the 2 
phone and ring (FG1.3). Lift the phone and ring (FG1.4), and say 3 
"How are you feeling today?" You know, "I'm feeling pretty (poor)". 4 
There's nothing out there, there's nobody out there. And that's 5 
because we're in limbo.” FG1.1 6 
 7 
Discussion 8 
This novel study highlights the potentially negative impact that receiving and living 9 
with a MGUS diagnosis can have on patients, particularly at the point of diagnosis 10 
and time of follow-up appointments. Although receiving an MGUS diagnosis rarely 11 
had a life-changing impact, it did cause patients to re-evaluate their lives and to 12 
question their mortality. Most patients had a poor level of understanding of MGUS. 13 
Patients highlighted some issues in current MGUS service provision, especially in 14 
relation to information provision, but were positive about active surveillance 15 
provided by the nurse-led telephone clinic. Information was a powerful tool for 16 
patients, with good information and communication giving rise to improved 17 
understanding and reduced anxiety. The lack of available support for patients and 18 
their unwillingness to talk about MGUS to their families and friends, due to their own 19 
poor knowledge about MGUS and to avoid causing others anxiety was an issue for 20 
some patients. 21 
 22 
The emotional impact of MGUS was complex and nuanced to each individual. At the 23 
initial diagnosis, all patients reported experiencing shock at being diagnosed with an 24 
asymptomatic condition linked to cancer. This shock was similar to that reported for 25 
receiving positive results from population-level cancer screening (De Morgan et al., 26 
2002; Prinjha et al., 2011), other premalignant conditions (Gough et al., 2003; 27 
Hounsgaard et al., 2007; Kennedy et al., 2008; Shylasree et al., 2008) and 28 
haematological malignancies (Swash et al., 2016). For many patients, this shock 29 
developed into anxiety and fear; the potential of developing cancer remained an 30 
active concern in the weeks and months following diagnosis. This is similar to the 31 
experiences of MM patients who reported having a sudden and shocking 32 
confrontation with their mortality, by a condition that they had never heard of 33 
(Hauksdóttir et al., 2017). This anxiety often regresses when chronic illness patients 34 





similar to the experiences reported by the MGUS patients in this study. MGUS 1 
patients outlined the initial diagnosis period as having the highest psychosocial 2 
impact on their lives and an area where intervention could be implemented in the 3 
future. As most of the patients were several years’ post-diagnosis, further research on 4 
newly diagnosed patients may provide greater insight into immediate impact of 5 
receiving a MGUS diagnosis.  6 
 7 
Knowledge of MGUS was one of the strongest messages from the collective voice of 8 
the participants. Overall, patients had poor knowledge of MGUS at diagnosis. There 9 
was a clear distinction between the patients with MGUS knowledge and those with 10 
less knowledge. Those with more knowledge appeared to experience less anxiety and 11 
improved coping. In the wider MM literature, MM patients reported the initial 12 
gathering of information and developing knowledge as important to acquaint 13 
themselves with their condition and reduce their distress (Hauksdóttir et al., 2017). 14 
 15 
Patients are often unable to absorb verbal information at diagnosis (Kessels, 2003). 16 
Anxiety and isolation can result if the information from HCPs is considered to be 17 
lacking, confusing, or inadequately explained (Prinjha et al., 2011). Many MGUS 18 
patients reported not receiving an information leaflet at diagnosis, one of the most 19 
frequent sources of healthcare information for patients (Kenny et al., 1998; Meredith 20 
et al., 1995). However, there may be a recall bias in not recounting receiving the 21 
information. However in our previous research, only 42% of haematologists provided 22 
information booklets at all diagnoses (McShane et al., 2017). Nevertheless, receiving 23 
an information leaflet was linked to a more positive post-diagnosis experience. While 24 
acknowledging their condition may be lower priority for their doctor’s time 25 
(compared to cancer patients), the need for more doctor-patient communication and 26 
psychosocial care for MGUS patients was highlighted. Online searching was 27 
described as difficult with patients reporting contradictory and confusing information 28 
about MGUS. This finding is not surprising as haematological malignancies have 29 
previously been reported as being among the least well understood malignancies by 30 
patients (Department of Health, 2012).  31 
 32 
The telephone clinic was universally preferred to the hospital clinic by patients for 33 
reducing anxiety related to visiting the “cancer place”, and convenience (time and 34 





the outreach model as proposed by Rawstron et al. (2007). Our study adds to the 1 
growing literature of positive patient-reported experiences with telephone clinics 2 
(Rawstron et al., 2007) and suggests that CNS-led clinics are a useful addition to 3 
MGUS service provision. The COVID-19 pandemic has increased tele-4 
medicine/remote monitoring, which may accelerate development of MGUS 5 
telephone clinics nationally and internationally. Some patients felt their wait time 6 
between phlebotomy and receiving results was too long and extended their anxiety. 7 
It would therefore be useful for service providers, to consider mechanisms to reduce 8 
the length of this waiting period. 9 
 10 
MGUS patients were often reluctant to share details of their diagnosis with others 11 
outside their immediate family circle, due to low awareness and the feeling that 12 
other’s issues were more important; especially if cancer related. This was felt by some 13 
participants as obstructing their ability to cope with the diagnosis. Compared to the 14 
support available for cancer patients, MGUS patients felt peer support and support 15 
groups were lacking. Similar to other premalignant conditions (De Morgan et al., 16 
2002; Dowswell et al., 2012; Kennedy et al., 2008), MGUS patients agreed that there 17 
was benefit in meeting other patients to discuss shared experiences. Patients 18 
attending the focus groups reported positive experiences in being able to see and 19 
talk (often for the first time) to others with MGUS. An official website featuring life 20 
stories and blogs was also advocated by patients. This style is in keeping with 21 
mainstream health websites including ‘NHS Choices’ in the United Kingdom and 22 
charity websites who aim to supplement scientific facts with experiential information 23 
(Kelly et al., 2013).  24 
 25 
Clinical Implications 26 
 27 
A number of clear considerations came from the patients in this study. 28 
 29 
1. In line with the UK/Nordic guidelines (Bird et al., 2009), patient-friendly 30 
information and support is necessary at the point of diagnosis and thereafter for 31 
MGUS patients. Information booklets are available (e.g. Myeloma UK, Macmillan 32 
and the International Myeloma Foundation), however our results suggest these 33 
are not routinely provided at diagnosis. The information should be offered in 34 
various formats (verbal, paper and online) as patient needs differ. Information 35 
should advise on future follow-up procedures, disease progression and 36 





in information leaflets was also suggested by patients who want to ‘see’ what 1 
other MGUS patients look like.  2 
 3 
2. Many patients were diagnosed/followed-up initially in the local hematology 4 
department, however patients recalled this negatively as the ‘cancer place’ owing 5 
to cancer patients receiving their treatments in the same department. Improving 6 
the clinical environment may reduce patient anxiety, improve knowledge 7 
absorption and reduce future psychosocial distress.  8 
 9 
3. The use of telephone clinics was positively endorsed by MGUS patients in this 10 
study. Telephone clinics reduce patient burden by reducing hospital visits, which 11 
can incur both financial and psychosocial costs (Overend et al., 2008; Rawstron et 12 
al., 2007);the feasibility of expanding this service should be explored 13 
 14 
Strengths and limitations 15 
Our study is based on the lived experiences of 14 MGUS patients in two health and 16 
social care trusts in Northern Ireland. Our sample size is comparable to other 17 
premalignant studies which have reported on small sample sizes (under 16) 18 
(Hounsgaard et al., 2007; Kennedy et al., 2008; Lee Mortensen and Adeler, 2010; Likes 19 
et al., 2008; Prinjha et al., 2006; Pruitt et al., 2008). Despite a small sample data, 20 
However, despite this, we feel as a research team that this was an accurate 21 
representation of the views of NI MGUS patients but that there were further insights 22 
that could found with more participants in some sub-themes, which may have not 23 
reached data saturation.  24 
When considering the transferability of our findings to the wider MGUS population, 25 
the younger age of participants (present study 55.9 vs 74 years old; Li et al., 2016), 26 
and low risk MGUS profile should be considered. Due to the small numbers and 27 
similar age range (predominantly 50-70 years old), we were unable to explore the 28 
impact of age on experiences  However, as patients diagnosed with MGUS at a 29 
younger age live longer with the knowledge of their condition and have an increased 30 
lifetime risk of developing MM; this younger group may receive a greater benefit 31 
from future interventions.   32 
Combining the focus group and interview data has potential drawbacks. The 33 
increased interaction and sharing in the focus group led the data into different 34 
avenues which were not as dynamic in the dyadic interviews. These diversions 35 





MGUS diagnosis. Correspondingly, the in-depth nature of interviews and individual 1 
experiences provided finer details. Combining these modalities can cause 2 
disconnects between the experiences of focus group and interview participants and 3 
required the analysis to consider if the modality influenced this. However, we found 4 
the codes and themes were consistent during the analysis of both modalities. The 5 
use of the patient’s CNSs as recruiters opens the possibility of recruitment bias, 6 
however this is a common recruitment mechanism in premalignant conditions 7 
(Kennedy et al., 2012; Pruitt et al., 2008). Information was not collected on those who 8 
did not indicate interest in participating 9 
 10 
Conclusions 11 
Life-long surveillance provides patients with a periodical reminder of their MGUS 12 
diagnosis and its potential progression to cancer, which can cause anxiety.  Measures 13 
such as provision of information leaflets to all patients at diagnosis, patient support 14 
groups, improved HCP communication and diagnosis/follow-up within a non-cancer 15 




Conflicts of Interest and sources of Funding Statement  20 
The authors have declared no conflict of interest exists. The corresponding author 21 
had full access to all the data and final responsibility for the decision to submit for 22 
publication. Funding for this study was provided by a Cancer Translational Research 23 
Group Young Investigator Grant. At the time of the study, Dr Charlene McShane was 24 
in receipt of a Cancer Research UK Population Sciences Research Fellowship. 25 






References  2 
Barbour, C.R., 2014. Doing Focus Groups. Sage Publications, Inc., London. 3 
Bird, J., Behrens, J., Westin, J., Turesson, I., Drayson, M., Beetham, R., D’Sa, S., Soutar, 4 
R., Waage, A., Gulbrandsen, N., Gregersen, H., Low, E., 2009. UK Myeloma Forum 5 
(UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the 6 
investigation of newly detected M-proteins and the management of monoclonal 7 
gammopathy of undetermined significance (MGUS). Br. J. Haematol. 147, 22–42. 8 
https://doi.org/10.1111/j.1365-2141.2009.07807.x 9 
Braun, V., Clarke, V., 2006. Using thematic analysis in psychology. Qual. Res. Psychol. 10 
3, 77–101. https://doi.org/10.1191/1478088706qp063oa 11 
De Morgan, S., Redman, S., White, K.J., Cakir, B., Boyages, J., 2002. “Well, have I got 12 
cancer or haven’t I?” The psycho-social issues for women diagnosed with ductal 13 
carcinoma in situ. Heal. Expect. 5, 310–318. https://doi.org/10.1046/j.1369-14 
6513.2002.00199.x 15 
Department of Health, 2012. Cancer patient experience survey 2011/12. National 16 
report. London. 17 
Dowswell, G., Ryan, A., Taylor, A., Daley, A., Freemantle, N., Brookes, M., Jones, J., 18 
Haslop, R., Grimmett, C., Cheng, K.-K., Sue, W., 2012. Designing an intervention 19 
to help people with colorectal adenomas reduce their intake of red and 20 
processed meat and increase their levels of physical activity: a qualitative study. 21 
BMC Cancer 12, 255. https://doi.org/10.1186/1471-2407-12-255 22 
Gough, M.D., Gilliam, A.D., Stoddard, C.J., Ackroyd, R., 2003. Barrett’s esophagus : 23 
patient information and the Internet. The patient’s perspective. Dis. Esophagus 24 
57–59. 25 
Hauksdóttir, B., Klinke, M.E., Gunnarsdóttir, S., Björnsdóttir, K., 2017. Patients’ 26 
Experiences With Multiple Myeloma: A Meta-Aggregation of Qualitative Studies. 27 
Oncol. Nurs. Forum 44, E64–E81. https://doi.org/10.1188/17.ONF.E64-E81 28 
Hounsgaard, L., Petersen, L.K., Pedersen, B.D., 2007. Facing possible illness detected 29 
through screening-Experiences of healthy women with pathological cervical 30 
smears. Eur. J. Oncol. Nurs. 11, 417–423. 31 
https://doi.org/10.1016/j.ejon.2007.04.005 32 
International Myeloma Working Group, 2003. Criteria for the classification of 33 
monoclonal gammopathies, multiple myeloma and related disorders. Br. J. 34 
Haematol. 121, 749–57. https://doi.org/10.1046/j.1365-2141.2003.04355.x 35 
Kelly, L., Jenkinson, C., Ziebland, S., 2013. Measuring the effects of online health 36 





Patient Educ. Couns. 93, 433–438. https://doi.org/10.1016/j.pec.2013.03.012 1 
Kennedy, F., Harcourt, D., Rumsey, N., 2012. The shifting nature of women’s 2 
experiences and perceptions of ductal carcinoma in situ. J Adv Nurs 68, 856–867. 3 
https://doi.org/10.1111/j.1365-2648.2011.05788.x 4 
Kennedy, F., Harcourt, D., Rumsey, N., 2008. The challenge of being diagnosed and 5 
treated for ductal carcinoma in situ (DCIS). Eur. J. Oncol. Nurs. 12, 103–11. 6 
https://doi.org/10.1016/j.ejon.2007.09.007 7 
Kenny, T., Wilson, R.G., Purves, I.N., Clark, J., Newton, L.D., Newton, D.P., Moseley, D. 8 
V, 1998. A PIL for every ill? Patient information leaflets (PILs): a review of past, 9 
present and future use. Fam. Pract. https://doi.org/10.1093/FAMPRA/15.5.471 10 
Kessels, R.P.C., 2003. Patients’ memory for medical information. J. R. Soc. Med. 96, 11 
219–22. https://doi.org/10.1258/jrsm.96.5.219 12 
Kyle, R.A., Buadi, F., Vincent Rajkumar, S., 2011. Management of monoclonal 13 
gammopathy of undetermined significance (MGUS) and smoldering multiple 14 
myeloma (SMM). Oncology 25, 578–86. https://doi.org/167682 [pii] 15 
Kyle, R.A., Durie, B.G.M., Rajkumar, S. V, Landgren, O., Blade, J., Merlini, G., Kröger, N., 16 
Einsele, H., Vesole, D.H., Dimopoulos, M., San Miguel, J., Avet-Loiseau, H., Hajek, 17 
R., Chen, W.M., Anderson, K.C., Ludwig, H., Sonneveld, P., Pavlovsky, S., Palumbo, 18 
A., Richardson, P.G., Barlogie, B., Greipp, P., Vescio, R., Turesson, I., Westin, J., 19 
Boccadoro, M., International Myeloma Working Group, Kyle, R.A., Durie, B.G.M., 20 
Rajkumar, S. V, Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, 21 
D.H., Dimopoulos, M., San Miguel, J., Avet-Loiseau, H., Hajek, R., Chen, W.M., 22 
Anderson, K.C., Ludwig, H., Sonneveld, P., Pavlovsky, S., Palumbo, A., Richardson, 23 
P.G., Barlogie, B., Greipp, P., Vescio, R., Turesson, I., Westin, J., Boccadoro, M., 24 
2010. Monoclonal gammopathy of undetermined significance (MGUS) and 25 
smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives 26 
risk factors for. Leukemia 24, 1121–7. https://doi.org/10.1038/leu.2010.60 27 
Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F., 28 
Melton, L.J., 2002. A long-term study of prognosis in monoclonal gammopathy 29 
of undetermined significance. N. Engl. J. Med. 346, 564–9. 30 
https://doi.org/10.1056/NEJMoa01133202 31 
Kyle, R.A., Therneau, T.T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F., Offord, J.R., 32 
Dispenzieri, A., Katzmann, J. a, Melton, L.J., 2006. Prevalence of monoclonal 33 
gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362–1369. 34 
https://doi.org/10.1002/ajh.22095 35 
Lamb, M., Kane, E., Smith, A., Roman, E., 2019. Hospital activity before and after 36 
diagnosis of monoclonal gammopathy of undetermined significance (MGUS), in: 37 





Landgren, O., Graubard, B.I., Kumar, S., Kyle, R.A., Katzmann, J.A., Murata, K., Costello, 1 
R., Dispenzieri, A., Caporaso, N., Mailankody, S., Korde, N., Hultcrantz, M., 2 
Therneau, T.M., Larson, D.R., Cerhan, J.R., Rajkumar, S. V., 2017. Prevalence of 3 
myeloma precursor state monoclonal gammopathy of undetermined 4 
significance in 12372 individuals 10-49 years old: a population-based study from 5 
the National Health and Nutrition Examination Survey. Blood Cancer J. 7, e618. 6 
https://doi.org/10.1038/bcj.2017.97 7 
Landgren, O., Gridley, G., Turesson, I., Caporaso, N.E., Goldin, L.R., Baris, D., Fears, T.R., 8 
Hoover, R.N., Linet, M.S., 2006. Risk of monoclonal gammopathy of 9 
undetermined significance (MGUS) and subsequent multiple myeloma among 10 
African American and white veterans in the United States. Blood 107, 904–906. 11 
https://doi.org/10.1182/blood-2005-08-3449 12 
Landgren, O., Katzmann, J., Hsing, A., 2007. Prevalence of monoclonal gammopathy 13 
of undetermined significance among men in Ghana. Mayo Clin. Proc. 82, 1468–14 
1473. 15 
Lee Mortensen, G., Adeler, A.L., 2010. Qualitative study of women’s anxiety and 16 
information needs after a diagnosis of cervical dysplasia. J. Public Health 17 
(Bangkok). 18, 473–482. https://doi.org/10.1007/s10389-010-0330-1 18 
Li, J., Smith, A., Crouch, S., Oliver, S., Roman, E., 2016. Estimating the prevalence of 19 
hematological malignancies and precursor conditions using data from 20 
Haematological Malignancy Research Network (HMRN). Cancer Causes Control 21 
27, 1019–1026. https://doi.org/10.1007/s10552-016-0780-z 22 
Likes, W.M., Russell, C., Tillmanns, T., 2008. Women’s Experiences With Vulvar 23 
Intraepithelial Neoplasia. J. Obstet. Gynecol. Neonatal Nurs. 37, 640–646. 24 
https://doi.org/10.1111/j.1552-6909.2008.00291.x 25 
Maatouk, I., He, S., Hummel, M., Hemmer, S., Hillengass, M., Goldschmidt, H., 26 
Hartmann, M., Herzog, W., Hillengass, J., 2019. Patients with precursor disease 27 
exhibit similar psychological distress and mental HRQOL as patients with active 28 
myeloma. Blood Cancer J. 9, 1–4. https://doi.org/10.1038/s41408-019-0172-1 29 
McShane, C.M., Murphy, B., Lim, K.H., Anderson, L.A., 2017. Monoclonal gammopathy 30 
of undetermined significance (MGUS) as viewed by haematology healthcare 31 
professionals. Eur. J. Haematol. 1–7. https://doi.org/10.1111/ejh.12962 32 
Meredith, P., Emberton, M., Wood, C., 1995. New directions in information for 33 
patients. BMJ 311, 4–5. 34 
Mishel, M., 1999. Uncertainty in chronic illness. Annu. Rev. Nurs. Res. 17, 269–294. 35 
Morse, J.M., Barrett, M., Mayan, M., Olson, K., Spiers, J., 2002. Verification Strategies 36 
for Establishing Reliability and Validity in Qualitative Research. Int. J. Qual. 37 





Nowell, L.S., Norris, J.M., White, D.E., Moules, N.J., 2017. Thematic Analysis : Striving to 1 
Meet the Trustworthiness Criteria 16, 1–13. 2 
https://doi.org/10.1177/1609406917733847 3 
Overend, A., Khoo, K., Delorme, M., Krause, V., Avanessian, A., Saltman, D., 2008. 4 
Evaluation of a nurse-led telephone follow-up clinic for patients with indolent 5 
and chronic hematological malignancies: A pilot study. Can. Oncol. Nurs. J. 18, 6 
64–68. https://doi.org/10.5737/1181912x1826468 7 
Prinjha, S., Evans, J., McPherson, A., 2006. Women’s information needs about ductal 8 
carcinoma in situ before mammographic screening and after diagnosis: a 9 
qualitative study. J. Med. Screen. 2006 13, 110–114. 10 
Prinjha, S., Evans, J., Ziebland, S., McPherson,  a, 2011. “A mastectomy for something 11 
that wasn’t even truly invasive cancer”. Women’s understandings of having a 12 
mastectomy for screen-detected DCIS: a qualitative study. J. Med. Screen. 18, 13 
34–40. https://doi.org/10.1258/jms.2011.010143 14 
Pruitt, S.L., Parker, P.A., Follen, M., Basen-Engquist, K., 2008. Communicating 15 
colposcopy results: what do patients and providers discuss? J. Low. Genit. Tract 16 
Dis. 12, 95–102. https://doi.org/10.1097/LGT.0b013e31815a5142 17 
QSR International Pty Ltd, 2015. NVivo qualitative data analysis Software. 18 
Rawstron, A.C., Jones, R.A., Ferguson, C., Hughes, G., Selby, P., Reid, C., Dalal, S., 19 
Howard, M., Smith, G., Hillmen, P., Owen, R.G., Jack, A.S., 2007. Outreach 20 
monitoring service for patients with indolent B-cell and plasma cell disorders: a 21 
UK experience. Br. J. Haematol. 139, 845–848. https://doi.org/10.1111/j.1365-22 
2141.2007.06864.x 23 
Shylasree, T.S., Karanjgaokar, V., Tristram, A., Wilkes, A.R., MacLean, A.B., Fiander, A.N., 24 
2008. Contribution of demographic, psychological and disease-related factors to 25 
quality of life in women with high-grade vulval intraepithelial neoplasia. Gynecol. 26 
Oncol. 110, 185–189. https://doi.org/10.1016/j.ygyno.2008.04.023 27 
Smith, D.P., Supramaniam, R., King, M.T., Ward, J., Berry, M., Armstrong, B.K., 2007. 28 
Age, health, and education determine supportive care needs of men younger 29 
than 70 years with prostate cancer. J. Clin. Oncol. 25, 2560–2566. 30 
https://doi.org/10.1200/JCO.2006.09.8046 31 
Stokes, D., Bergin, R., 2006. Methodology or “methodolatry”? An evalution of focus 32 
and depth interviews. Qual. Mark. Res.  An Int. J. Artic. 9, 26–37. 33 
https://doi.org/10.1108/13522750610640530 34 
Swash, B., Hulbert-Williams, N., Bramwell, R., 2016. ’Haematological cancers, they’re a 35 
funny bunch: A qualitative study of non-Hodgkins lymphoma patient 36 






Therneau, T.M., Kyle, R.A., Melton, L.J., Larson, D.R., Benson, J.T., Colby, C.L., 1 
Dispenzieri, A., Kumar, S., Katzmann, J.A., Cerhan, J.R., Rajkumar, S.V., 2012. 2 
Incidence of monoclonal gammopathy of undetermined significance and 3 
estimation of duration before first clinical recognition. Mayo Clin. Proc. 87, 1071–4 
9. https://doi.org/10.1016/j.mayocp.2012.06.014 5 
Wadhera, R.K., Rajkumar, S.V., 2010. Prevalence of monoclonal gammopathy of 6 







Tables and Figures  14 
Table 1 Demographic characteristics of the patients 15 
CHARACTERISTICS NO. PATIENTS/ MEAN 
(%/RANGE) 
GENDER     
 Male 8 (57) 
 Female  6 (43) 
AGE     
 41-50 2 (14.3) 
 51-60 5 (35.7) 
 61-70 6 (42.8) 
 71-80 1 (7.2) 





 Married 13 (92.8) 
 Divorced 1 (7.2) 
LEVEL OF EDUCATION  
 Finished Secondary School ('O' Levels) 3 (21.4) 
 Finished Secondary School ('A' Levels) 3 (21.4) 
 Further Education (attended a Technical 
College) 
3 (21.4) 
 Undergraduate/Master’s degree 5 (35.8) 
AGE AT DIAGNOSIS   
 Mean age in years  55.9 (45-74) 
TELEPHONE REVIEW   
 Follow-up time in months  5.6 (3-12) 
PLACE OF RESIDENCE     
 Urban 9 (54) 
 Rural 5 (36) 
OTHER LONG-TERM CONDITIONS     
 Yes 6 (43) 
 No 8 (57) 
 1 
 2 
Table 2 Sociodemographic factors of individual patients 3 









FG1.2 Male 61-70 Further Education 














FG2.2 Male 51-60 ‘A’ Levels 
TI.1 Male 51-60 ‘A’ Levels 
TI.2 Female 51-60 ‘O’ Levels 





TI.5 Female 71-80 ‘O’ Levels 
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